Global ENT Disorder Treatment Market 2017-2021

  • ID: 4240188
  • Report
  • Region: Global
  • 70 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • ALK
  • AstraZeneca
  • GSK
  • Merck
  • Novartis
  • Pfizer
  • MORE
About ENT Disorder Treatment

ENT also known as otolaryngology, is an area of medicine that deals with disorders of ear, nose, and throat. Dysfunction of these body parts can affect quality of life and in certain cases may even lead to medical emergency. The market encompasses drugs that are used for the treatment of the ENT disorder. It mainly considers the various drug class used for the treatment of numerous symptoms of the disease. The major ENT disorders included in the report are rhinitis, sinusitis, otitis media, and tonsillitis.

The analysts forecast the global ENT disorder treatment market to grow at a CAGR of 2.17% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global ENT disorder treatment market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales from both branded and generic drugs.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global ENT Disorder Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- ALK
- GSK
- Novartis
- Sanofi

Other prominent vendors
- Allergan
- AstraZeneca
- Dr. Reddy's Laboratories
- Lupin
- Merck
- Mylan
- Otonomy
- Pfizer
- Sun Pharma
- Teva Pharmaceuticals

Market drivers
- Deteriorating environmental conditions.
- For a full, detailed list, view the full report

Market challenges
- Growing cases of anti-bacterial resistance.
- For a full, detailed list, view the full report

Market trends
- Growing consolidation in industry particularly for rhinitis.
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the Key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • ALK
  • AstraZeneca
  • GSK
  • Merck
  • Novartis
  • Pfizer
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Key market highlights
PART 05: Disease overview

PART 06: Market landscape
  • Market overview
  • Five forces analysis
PART 07: Pipeline landscape

PART 08: Market segmentation by disease
  • Global rhinitis treatment market
  • Global sinusitis treatment market
  • Global otitis media treatment market
  • Global tonsillitis treatment market
PART 09: Geographical segmentation
  • ENT disorder treatment market in Americas
  • ENT disorder treatment market in EMEA
  • ENT disorder treatment market in APAC
PART 10: Decision framework

PART 11: Drivers and challenges
  • Market drivers
  • Impact of drivers on key customer segments
  • Market challenges
  • Impact of challenges on key customer segments
PART 12: Market trends
  • Growing consolidation in industry
PARTicularly for rhinitis
  • Increase in research on allergic disorders
  • Awareness about controlled usage of antibiotics
PART 13: Vendor landscape
  • Competitive landscape
PART 14: Key vendor analysis
  • ALK
  • GSK
  • Novartis
  • Sanofi
  • Other prominent vendors
PART 15: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Some major treatments associated with sinusitis
Exhibit 02: Snapshot: Global ENT disorder treatment market
Exhibit 03: Global ENT disorder treatment market 2016-2021 ($ millions)
Exhibit 04: Opportunity analysis: Global ENT disorder treatment market
Exhibit 05: Five forces analysis
Exhibit 06: Key pipeline by vendors
Exhibit 07: Pipeline landscape
Exhibit 08: Global ENT disorder treatment market segmentation by disease type
Exhibit 09: Market snapshot: Global ENT disorder market by disease type 2016-2021
Exhibit 10: Types of rhinitis
Exhibit 11: Major types of allergic rhinitis
Exhibit 12: Global rhinitis treatment market 2016-2021 ($ millions)
Exhibit 13: Types of sinusitis
Exhibit 14: Some drugs approved for sinusitis
Exhibit 15: Global sinusitis treatment market 2016-2021 ($ millions)
Exhibit 16: Otitis media therapy in pipeline
Exhibit 17: Global otitis media treatment market 2016-2021 ($ millions)
Exhibit 18: Global tonsillitis treatment market 2016-2021 ($ millions)
Exhibit 19: ENT disorder treatment market by geography 2016 and 2021
Exhibit 20: ENT disorder treatment market by geography 2016-2021 ($ millions)
Exhibit 21: Market scenario in Americas
Exhibit 22: ENT disorder treatment market in Americas 2016-2021 ($ millions)
Exhibit 23: Market scenario in EMEA
Exhibit 24: ENT disorder treatment market in EMEA 2016-2021 ($ millions)
Exhibit 25: Market scenario in APAC
Exhibit 26: ENT disorder treatment market in APAC 2016-2021 ($ millions)
Exhibit 27: ENT disorders triggered by various pollutants
Exhibit 28: Adult population with sinusitis and chronic rhinitis in US 2014 (million)
Exhibit 29: Impact of drivers
Exhibit 30: Antibiotic resistance development steps
Exhibit 31: Few landmark generic version of branded drugs
Exhibit 32: Impact of challenges
Exhibit 33: Major causes of antibiotic resistance
Exhibit 34: Competitive structure analysis of global ENT disorder treatment market 2016
Exhibit 35: Competitive analysis of global ENT disorder treatment market
Exhibit 36: ALK: Key highlights
Exhibit 37: ALK: Strength assessment
Exhibit 38: ALK: Strategy assessment
Exhibit 39: ALK: Opportunity assessment
Exhibit 40: GSK: Key highlights
Exhibit 41: GSK: Strength assessment
Exhibit 42: GSK: Strategy assessment
Exhibit 43: GSK: Opportunity assessment
Exhibit 44: GSK: YoY growth rate of Avamys/Veramyst 2014 and 2015 ($ millions)
Exhibit 45: Novartis: Key highlights
Exhibit 46: Novartis: Strength assessment
Exhibit 47: Novartis: Strategy assessment
Exhibit 48: Novartis: Opportunity assessment
Exhibit 49: Sanofi: Key highlights
Exhibit 50: Sanofi: Strength assessment
Exhibit 51: Sanofi: Strategy assessment
Exhibit 52: Sanofi: Opportunity assessment
Exhibit 53: Sanofi: YoY growth rate of Allegra 2014 and 2015 ($ millions)
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • ALK
  • AstraZeneca
  • GSK
  • Merck
  • Novartis
  • Pfizer
  • MORE
New Report Released: – Global ENT Disorder Treatment Market 2017-2021

The author of the report recognizes the following companies as the key players in the global ENT disorder treatment market: ALK, GSK, Novartis, and Sanofi.

Other Prominent Vendors in the market are: Allergan, AstraZeneca, Dr. Reddy's Laboratories, Lupin, Merck, Mylan, Otonomy, Pfizer, Sun Pharma, and Teva Pharmaceuticals.

Commenting on the report, an analyst from the research team said: “One trend in market is increase in research on allergic disorders. Allergic diseases such as rhinitis, if not managed properly, have chances of developing into organizations around the world are working to have a better understanding of the pathogenesis of allergic diseases. For instance, The Australasian Society of Clinical Immunology and Allergy, Allergy and Anaphylaxis Australia, and the European Academy of Allergy and Clinical Immunology are working for a better understanding of allergic diseases.”

According to the report, one driver in market is deteriorating environmental conditions. Deteriorating environmental conditions is one of the major reasons for the rising prevalence of ENT disorders such as rhinitis. For instance, perennial allergic rhinitis can prevail around the year and is often the result of sensitivity to mold on wallpaper, pet hair, carpeting, houseplants, and upholstery. Also, congested living conditions and high pollution levels are known to be some of the primary factors leading to sinusitis. Studies have suggested that allergic rhinitis can be aggravated by certain polluting agents such as automobile engine emission. The problem is more severe in urban areas specifically in developing countries like India and China. It is estimated that more than three-fourth of the urban population is exposed to the air quality that exceeds the WHO limits.

Further, the report states that one challenges in market is growing cases of anti-bacterial resistance. Antimicrobial resistance is one of the major public health challenges faced globally, and has been accelerated by the overuse of antibiotics across the globe. Overprescribing antibiotics is a common problem in primary care, where most of the infections are caused by viruses. It is estimated that general practitioners prescribe 90% of the total antibiotic prescriptions, where respiratory tract infections and respiratory disorders are the major causes of prescription. Per the data provided by the CDC more than two million people worldwide, each year, are identified as being antibiotic resistant. Antibiotic resistance adds avoidable and considerable cost on the already overburdened healthcare system. As per the CDC, antibiotic resistance is estimated to have an economic burden of $55 billion on the US per year. The CDC indicates that about 235 million antibiotic doses are administered per year, of these 20%-50% are not needed.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • ALK
  • GSK
  • Novartis
  • Sanofi
  • Allergan
  • AstraZeneca
  • Dr Reddy's Laboratories
  • Lupin
  • Merck
  • Mylan
  • Otonomy
  • Pfizer
  • Sun Pharma
  • Teva Pharmaceuticals
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll